Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Atyr Pharma, Inc.
A San Diego biotech developing medicines from tRNA synthetases, the enzymes best known for building proteins inside cells. Its lead drug candidate, efzofitimod, targets fibrosis and inflammation, such as scarring of the lungs. Founded in 2005 by scientists Paul Schimmel and Xiang-Lei Yang, it grew out of their discovery that these enzymes also act outside cells as signaling molecules — a twist that gives the company its name, taken from tyrosyl-tRNA synthetase.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.02 Termination of a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing